ArticleMolecular imaging and biology2024
Pre-treatment
Article in Molecular imaging and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Pooled it
- Baseline PSMA-ligand PET/CT as a predictive biomarker for early progression in metastatic castration-resistant prostate cancer patients undergoing [177Lu]Lu-PSMA-617 radioligand therapy.Annals of nuclear medicine · 2026Article
- [Research square · 2026Article
- Baseline PSMA PET/CT Biomarkers for Patient Selection in [Pharmaceuticals (Basel, Switzerland) · 2026Review
- Lesion-level quantitative Lu-177 PSMA SPECT/CT SUV metrics are associated with interim treatment response in mCRPC: a PET-correlated study.Annals of nuclear medicine · 2026Article
- Predictive imaging biomarkers on whole-body diffusion-weighted MRI (WB-DWMRI) and [Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- The role of multimodality imaging in selection, response assessment, and follow-up of patients receivingInsights into imaging · 2026Article
- Study of predictive factors for response toFrontiers in medicine · 2025Article
- Predicting Response to [177Lu]Lu-PSMA Therapy in mCRPC Using Machine Learning.Journal of personalized medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the prognostic value of pre-treatment [ PROCEDURES: In this retrospective study, 81 patients who received [
resultsSixty patients (age:73 ± 8, PSA:185 ± 371) were included. Patients received at least one cycle of [
conclusionsA greater level of PSMA uptake, specifically higher tumour-to-background uptake in the hottest lesion, may hold substantial prognostic significance, considering both [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.